Dr. Ferrandiz
LightNews LightNews
banner
renatoferrandiz.bsky.social
Dr. Ferrandiz
@renatoferrandiz.bsky.social
36 followers 38 following 14 posts
M.D. M.H.A. Happy Chief Resident at North Alabama Medical Center and soon-to-be Rheumatology Fellow at UW!
Posts Replies Media Videos
renatoferrandiz.bsky.social
After a long day at work, finding my #ACR25 #RheumCat sticker waiting for me brought a smile.
Dr. @rheumcat.bsky.social makes Rheumatology easier to navigate through her dedication, motivation, and genuine care for her trainees. Her example inspires me every day, and I am forever grateful. 💙🐈‍⬛
November 11, 2025 at 1:50 AM
renatoferrandiz.bsky.social
Baby thinking if he should be a #Rheumatologist
November 1, 2025 at 4:46 PM
Reposted by Dr. Ferrandiz
alisonbays.bsky.social
Poster: subcutaneous tocilizumab may be more effective in #GCA than IV. So unfortunate that many of our seniors can only get IV due to health insurance 😢 #ACR25
October 26, 2025 at 6:01 PM
Reposted by Dr. Ferrandiz
alisonbays.bsky.social
I did comb through our #GCA Fast Track Clinic and also didn’t find seasonal variation but agree, sure feels like it is seasonal at times! #ACR25
October 26, 2025 at 6:17 PM
Reposted by Dr. Ferrandiz
alisonbays.bsky.social
Unfortunate information on #ANCA vasculitis and #GCA clinical trials showing poor representation of patients and a low number even reporting race. We need to do better. #ACR25
October 26, 2025 at 6:32 PM
renatoferrandiz.bsky.social
@uwrheum.bsky.social yay!
August 12, 2025 at 6:15 PM
Reposted by Dr. Ferrandiz
rheumcat.bsky.social
Congrats to @renatoferrandiz.bsky.social on the publication of the SPARTAN Clinical Year in Review

He transformed the talk that I gave into digestible figures and text

rdcu.be/euouC

cc @ruthjeannapier.bsky.social @mohamadbittarmd.bsky.social
@spondymd.bsky.social
@restovall.bsky.social
Spondyloarthritis Research and Treatment Network (SPARTAN) Clinical and Imaging Year in Review 2024
rdcu.be
July 2, 2025 at 11:39 AM
Reposted by Dr. Ferrandiz
rheumcat.bsky.social
Our work was cited in terms of diagnostic delay in axial spondyloarthritis

@renatoferrandiz.bsky.social
@spondymd.bsky.social
Two studies about diagnostic delay in axial spondyloarthritis: Magrey et al and Ferrandiz et al Dr Sibel Aydin presenting at the SPARTAN annual meeting
May 10, 2025 at 12:19 PM
Reposted by Dr. Ferrandiz
jrheumatol.bsky.social
Editor's Picks Spotlight

Disparities in Time to Diagnosis of Radiographic Axial Spondyloarthritis with Drs. Renato Ferrandiz-Espadin, Jean W. Liew and Maureen Dubreuil
@renatoferrandiz.bsky.social @rheumcat.bsky.social
@spondymd.bsky.social

📖 doi.org/10.3899/jrhe...

📽️ youtu.be/jXAe-dlbxsc
Editor's Picks Spotlight: Disparities in Time to Diagnosis of r-axSpA
YouTube video by The Journal of Rheumatology
youtu.be
April 25, 2025 at 4:02 PM
Reposted by Dr. Ferrandiz
jrheumatol.bsky.social
Editorial

Disparities in Diagnosis: A Call for Equity in Radiographic Axial Spondyloarthritis Care

📖 doi.org/10.3899/jrhe...
@umasschan.bsky.social

#socialdisparities #radiographic #axSpA
April 3, 2025 at 1:31 PM
Reposted by Dr. Ferrandiz
nancycomics.bsky.social
Nancy By Ernie Bushmiller
April 4,1950
NANCY BY ERNIE BUSHMILLER SLUGGO--WHY ARE YOU WEARING THAT OUTFIT? I'M GONNA MARCH IN A PARADE TODAY HOW DO YOU KEEP THAT BIG HAT FROM FALLING OFF? ( SLUGGO HAS A PLUMBER’S HELPER STUCK TO HIS HEAD)
April 4, 2025 at 6:58 PM
Reposted by Dr. Ferrandiz
sphealposting.bsky.social
Screenshot from pokemon ruby sapphire emerald, text says "spheal is trying"
April 4, 2025 at 6:53 PM
renatoferrandiz.bsky.social
Great days at the #ACP25
April 4, 2025 at 9:05 PM
Reposted by Dr. Ferrandiz
dailybunnies.bsky.social
April 4, 2025 at 8:10 PM
Reposted by Dr. Ferrandiz
jrheumatol.bsky.social
Research Article

Disparities in Time to Diagnosis of Radiographic Axial Spondyloarthritis

📖 www.jrheum.org/cgi/content/...
@renatoferrandiz.bsky.social @rheumcat.bsky.social @spondymd.bsky.social

#socialdisparities #radiographic #axSpA
April 3, 2025 at 4:41 PM
Reposted by Dr. Ferrandiz
spondymd.bsky.social
We found that diagnostic delay in axial spondyloarthritis was 21% longer (7 months) among people with a social need, using an accelerated failure time model. @jrheumatol.bsky.social @renatoferrandiz.bsky.social www.jrheum.org/content/52/4...
Disparities in Time to Diagnosis of Radiographic Axial Spondyloarthritis
Objective Radiographic axial spondyloarthritis (r-axSpA) has a 7-year average diagnostic delay. Although the effects of sex or gender on time to diagnosis have been evaluated, the role of social deter...
www.jrheum.org
April 1, 2025 at 2:21 PM
Reposted by Dr. Ferrandiz
nephjc.bsky.social
T3f: #NephJC
Obinutuzumab is currently tested as an add-on to lower steroids + high-dose MMF in LN. (Although, has anyone seen some palpable number on cortico total dose)

Key question: Can it reduce background immunosuppression?
March 12, 2025 at 1:51 AM
Reposted by Dr. Ferrandiz
nephjc.bsky.social
T3e: And their results: their definitions of CRR, PRR vary #NephJC
Any thoughts?
March 12, 2025 at 1:50 AM
Reposted by Dr. Ferrandiz
nephjc.bsky.social
T3d: Here are the trials with cell B blockers (yeah, induction, refractory LN, or whatever). Any notable differences in their design? #nephjc
March 12, 2025 at 1:49 AM
Reposted by Dr. Ferrandiz
nephjc.bsky.social
T3b: Obinutuzumab achieved sustained B-cell depletion (CD19+ <10/µL) in 95% of patients through week 76, outperforming Rituximab (~80% at week 52, LUNAR trial).
pubmed.ncbi.nlm.nih....

Obvious question: why REGENCY was positive and LUNAR negative? #nephJC
March 12, 2025 at 1:47 AM
Reposted by Dr. Ferrandiz
nephjc.bsky.social
T3a:
Short recap: #NephJC

🔹REGENCY trial confirms type 2 anti-CD20 efficacy in active lupus nephritis.
🔹Obinutuzumab + standard therapy improved renal response vs. placebo, aligning with NOBILITY trial findings
March 12, 2025 at 1:46 AM
Reposted by Dr. Ferrandiz
nephjc.bsky.social
T0l: #NephJC

Type II anti-CD20 mAbs (e.g., obinutuzumab) induce stronger B-cell cytotoxicity and enhanced phagocytosis, resulting in deeper and more sustained depletion, including in tissue-resident B-cell niches
March 12, 2025 at 1:18 AM
Reposted by Dr. Ferrandiz
nephjc.bsky.social
T0k: #NephJC

Based on BLISS-LN findings, belimumab is recommended by @kdigo.org as 1st line therapy

www.nephjc.com/news/...
March 12, 2025 at 1:18 AM
Reposted by Dr. Ferrandiz
nephjc.bsky.social
T0b: About 10–25% of patients will develop chronic kidney disease (CKD), and it has been described mortality of 10–20% at 10yrs #NephJC
🔸Studies= heterogeneous
🔸Demographics associated with worse renal outcomes: age (y<40 at the time of LN diagnosis) and Hispanic ethnicity pubmed.ncbi.nlm.nih....
March 12, 2025 at 1:08 AM
Reposted by Dr. Ferrandiz
nephjc.bsky.social
T0d: #NephJC
A recent #kireports electronic cohort-based study showed that compared with other primary GNs, in LN there is a slightly ⬇️risk of KRT. With LN-CKD 👉 higher risk of
🔸MACE HR 1.63 (95% CI, 1.32–2.02)
🔸all-cause mortality 1.65 (1.31–2.08)

www.kireports.org/ar...
March 12, 2025 at 1:10 AM